Boston Scientific Corporation (BSX) Stock Analysis
Boston Scientific’s sharp valuation reset offers a compelling but transitional medtech opportunity, balancing durable innovation-led growth against WATCHMAN softness, PFA competition, Penumbra integration risk, and elevated leverage.
Overview
Boston Scientific is a leading global medtech company focused on less-invasive devices across cardiovascular, endoscopy, urology, neuromodulation, and other high-acuity specialties. FY2025 sales reached $20.07B, up 19.9%, led by Cardiovascular growth and strong U.S. demand. Its model combines recurring single-use consumables, implants, and capital equipment, creating high-margin, sticky hospital relationships. Customers choose BSX for differentiated clinical outcomes, workflow efficiency, and strong evidence-backed product pipelines, positioning the company at the center of aging-population and chronic-disease tailwinds.